Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Calaspargase Pegol-mknl and Decitabine Combined with Venetoclax for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Trial Status: active

This phase II trial tests how well calaspargase pegol-mknl and decitabine in combination with venetoclax works in treating pediatric, adolescent and young adult patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Calaspargase pegol-mknl is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by stopping the growth of cancer cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Giving calaspargase pegol-mknl and decitabine in combination with venetoclax may kill more cancer cells in pediatric, adolescent and young adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.